Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A Cash Flow Conversion Efficiency
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A cash flow conversion efficiency. Based on the latest financial reports, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (600613) has a cash flow conversion efficiency ratio of 0.046x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥109.83 Million ≈ $16.07 Million USD) by net assets (CN¥2.41 Billion ≈ $352.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (1998–2025)
Cash flow conversion efficiency of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A from 1998 to 2025. This chart illustrates how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Shanghai Shenqi Pharmaceutical Investmen share price for real-time trading data and today's change.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A Cash Flow Conversion Ratio Explained
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A ranked by their cash flow conversion efficiency. Also see Shanghai Shenqi Pharmaceutical Investmen market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bumble Inc
NASDAQ:BMBL
|
0.087x |
|
Mstc Limited
NSE:MSTCLTD
|
-0.209x |
|
Gourmet Master Co Ltd
TW:2723
|
0.053x |
|
Jiangsu Huachen Transformer
SHG:603097
|
0.000x |
|
Beijing StarNeto Technology Co Ltd
SHE:002829
|
-0.003x |
|
Indonesian Paradise Property
JK:INPP
|
0.011x |
|
Seobu T&D Co. Ltd
KQ:006730
|
0.019x |
|
Iteos Therapeutics Inc
NASDAQ:ITOS
|
-0.086x |
Annual Cash Flow Conversion Efficiency for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (1998–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A from 1998 to 2025. Review how much free cash does Shanghai Shenqi Pharmaceutical Investmen generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.40 Billion ≈ $350.83 Million |
CN¥124.47 Million ≈ $18.21 Million |
0.052x | -39.36% |
| 2024-12-31 | CN¥2.43 Billion ≈ $355.12 Million |
CN¥207.79 Million ≈ $30.41 Million |
0.086x | -5.06% |
| 2023-12-31 | CN¥2.39 Billion ≈ $349.81 Million |
CN¥215.59 Million ≈ $31.55 Million |
0.090x | -32.96% |
| 2022-12-31 | CN¥2.37 Billion ≈ $347.27 Million |
CN¥319.23 Million ≈ $46.71 Million |
0.135x | +74.66% |
| 2021-12-31 | CN¥2.39 Billion ≈ $350.10 Million |
CN¥184.26 Million ≈ $26.96 Million |
0.077x | +80.90% |
| 2020-12-31 | CN¥2.33 Billion ≈ $340.61 Million |
CN¥99.10 Million ≈ $14.50 Million |
0.043x | -11.67% |
| 2019-12-31 | CN¥2.66 Billion ≈ $389.47 Million |
CN¥128.28 Million ≈ $18.77 Million |
0.048x | -15.67% |
| 2018-12-31 | CN¥2.60 Billion ≈ $380.28 Million |
CN¥148.53 Million ≈ $21.73 Million |
0.057x | +115.90% |
| 2017-12-31 | CN¥2.53 Billion ≈ $370.30 Million |
CN¥66.99 Million ≈ $9.80 Million |
0.026x | +11200.00% |
| 2016-12-31 | CN¥2.43 Billion ≈ $356.31 Million |
CN¥570.41K ≈ $83.47K |
0.000x | -98.22% |
| 2015-12-31 | CN¥2.29 Billion ≈ $334.49 Million |
CN¥30.12 Million ≈ $4.41 Million |
0.013x | +405.40% |
| 2014-12-31 | CN¥2.00 Billion ≈ $292.37 Million |
CN¥-8.62 Million ≈ $-1.26 Million |
-0.004x | -110.46% |
| 2013-12-31 | CN¥1.81 Billion ≈ $265.15 Million |
CN¥74.75 Million ≈ $10.94 Million |
0.041x | +183.60% |
| 2012-12-31 | CN¥226.61 Million ≈ $33.16 Million |
CN¥-11.18 Million ≈ $-1.64 Million |
-0.049x | -213.50% |
| 2011-12-31 | CN¥211.50 Million ≈ $30.95 Million |
CN¥-3.33 Million ≈ $-487.11K |
-0.016x | -109.17% |
| 2010-12-31 | CN¥192.37 Million ≈ $28.15 Million |
CN¥33.04 Million ≈ $4.83 Million |
0.172x | +309.61% |
| 2009-12-31 | CN¥183.43 Million ≈ $26.84 Million |
CN¥7.69 Million ≈ $1.13 Million |
0.042x | -65.35% |
| 2008-12-31 | CN¥208.82 Million ≈ $30.56 Million |
CN¥25.26 Million ≈ $3.70 Million |
0.121x | +54.40% |
| 2007-12-31 | CN¥204.29 Million ≈ $29.89 Million |
CN¥16.01 Million ≈ $2.34 Million |
0.078x | +344.25% |
| 2006-12-31 | CN¥188.49 Million ≈ $27.58 Million |
CN¥-6.05 Million ≈ $-884.87K |
-0.032x | -118.13% |
| 2005-12-31 | CN¥184.92 Million ≈ $27.06 Million |
CN¥32.72 Million ≈ $4.79 Million |
0.177x | +528.48% |
| 2004-12-31 | CN¥176.21 Million ≈ $25.79 Million |
CN¥4.96 Million ≈ $725.94K |
0.028x | -6.34% |
| 2003-12-31 | CN¥150.23 Million ≈ $21.98 Million |
CN¥4.52 Million ≈ $660.84K |
0.030x | -72.58% |
| 2002-12-31 | CN¥146.14 Million ≈ $21.38 Million |
CN¥16.02 Million ≈ $2.34 Million |
0.110x | +234.59% |
| 2001-12-31 | CN¥251.84 Million ≈ $36.85 Million |
CN¥-20.51 Million ≈ $-3.00 Million |
-0.081x | -209.56% |
| 2000-12-31 | CN¥361.16 Million ≈ $52.85 Million |
CN¥26.85 Million ≈ $3.93 Million |
0.074x | +864.07% |
| 1999-12-31 | CN¥336.74 Million ≈ $49.28 Million |
CN¥-3.28 Million ≈ $-479.48K |
-0.010x | -104.86% |
| 1998-12-31 | CN¥363.26 Million ≈ $53.16 Million |
CN¥72.67 Million ≈ $10.63 Million |
0.200x | -- |
About Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fiel… Read more